Time to Adapt Our Practice? The European Commission Has Restricted the Use of Fluoroquinolones since March 2019.

[1]  Daniel J. Shapiro,et al.  Opportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care Visits , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  K. Tatsugami,et al.  Predictive factors of biochemical recurrence after radical prostatectomy for high‐risk prostate cancer , 2018, International journal of urology : official journal of the Japanese Urological Association.

[3]  N. Vasdev,et al.  Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis , 2018, Prostate Cancer and Prostatic Diseases.

[4]  S. Doi,et al.  Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis , 2018, World Journal of Urology.

[5]  A. Basarab,et al.  The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography‐guided prostate biopsy in reducing infection rates: a systematic review , 2016, BJU international.

[6]  T. Değirmenci,et al.  The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: A prospective, randomized, and controlled clinical study. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[7]  R. Gardiner,et al.  The global burden of major infectious complications following prostate biopsy , 2015, Epidemiology and Infection.

[8]  Liangren Liu,et al.  Prophylactic Antibiotics in Prostate Biopsy: A Meta-Analysis Based on Randomized Controlled Trials. , 2015, Surgical infections.

[9]  A. Vicens Vicens,et al.  [Antibiotic prophylaxis in transrectal prostate biopsy]. , 2009, Actas urologicas espanolas.